1
ANOVA-Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2 Janssen-Cilag, São Paulo, SP, Brazil OBJECTIVES: To conduct cost-effectiveness and budget impact analysis (BIA) of OROS hydromorphone versus CR morphine and CR oxycodone for moderate to severe cancer pain from the public payer perspective in Brazil. METHODS: A decision tree followed by a Markov Model with a 12 month time horizon was developed with data from the Phase III trial Hanna 2008. The achievement of mild pain (worst pain scores < 4) was considered as outcome. Only direct medical costs were considered and unit costs were obtained from Brazilian offi cial lists. For the BIA, 10% of currently used CR morphine daily doses was substituted for equivalent OROS hydromorphone doses. The same rational was adopted for CR oxycodone comparison. Univariate deterministic sensitivity analyses showed that the results remained consistent through model parameters variation. RESULTS: OROS hydromorphone showed 1.66 additional months in mild pain per patient per year when compared to both CR morphine and CR oxycodone. Annual treatment costs were 2.401 BRL, 1.256 BRL and 5.114 BRL for OROS hydromorphone, CR morphine and CR oxycodone respectively. The incremental cost-effectiveness ratio was 689 BRL per additional month in mild pain per patient per year, when OROS hydromorphone was compared to CR morphine. Versus CR oxycodone, OROS hydromorphone was more effective with fewer costs, being cost saving (ICER -1,634 BRL). BIA results showed that the substitution of 10% of current utilization of CR morphine for OROS hydromorphone and CR oxycodone would result in a budgetary impact of 118,722 BRL and 347,295 BRL, respectively. CONCLUSIONS: OROS hydromorphone is cost saving when compared to CR oxycodone and is more cost-effective than CR oxycodone when both are compared to the current scenario of chronic cancer pain treatment with CR morphine, with a lower budgetary impact. Golimumab is a novel TNF-α inhibitor for treatment of patients with severe active ankylosing spondylitis (AS). This study evaluated the cost-effectiveness of golimumab and its appropriate comparators in the treatment of AS from UK National Health Service perspective. METHODS: A Markov model with an initial decision tree was developed to simulate the progression of a hypothetical cohort of active AS patients for 20 years. The primary outcome measure was quality-adjusted life-years (QALYs) estimated using Bath Ankylosing Spondilytis Functional Index (BASFI) whereas the primary response measure was ≥50% improvement in Bath Ankylosing Spondilytis Disease Activity Index (BASDAI) at 12 weeks. Direct costs including medication costs and AS management costs were included. Golimumab was compared with conventional treatment and other TNF-α inhibitors. Costs and outcomes were discounted at 3.5%. RESULTS: All TNF-α inhibitors were superior to conventional treatment and comparable to each other on BASDAI response. The incremental cost-effectiveness ratio (ICER) for golimumab was £15,353 per QALY compared to conventional treatment. The probability of golimumab being cost-effective at a threshold of £30,000/QALY was 92%. Compared to etanercept and adalimumab, golimumab generated marginally more QALYs at marginally more costs. CONCLUSIONS: Golimumab may be considered as a cost-effective treatment alternative for patients with AS. With comparable costs and effi cacy to other TNF-α inhibitors, golimumab's position in the treatment pathway is likely to be driven by patient and physician choice. The Dutch reimbursement policy for expensive inpatient medicines requires outcomes research after four years of temporary reimbursement. Based on a retrospective study, we explored the cost-effectiveness of bortezomib for relapsed/ refractory multiple myeloma in Dutch daily practice. METHODS: Detailed clinical data from a real-world cohort of 72 patients treated with bortezomib and 67 patients never treated with bortezomib were collected from medical records. Validity of the incremental cost-effectiveness was assessed by comparing baseline prognosis between bortezomib and non-bortezomib patients. Clinical effectiveness was evaluated by comparing Kaplan-Meier survival estimates. Costs of resource use from a hospital perspective were based on patient-level data. RESULTS: Prognostic factors for bortezomib patients were signifi cantly different compared to non-bortezomib patients. Incremental analyses for bortezomib versus non-bortezomib patients were therefore not performed. Total mean costs and median survival from start of relapsed/refractory treatment for bortezomib patients were c84,042 and 33.2 months. Bortezomib accounted for 21% of total costs among these patients. For non-bortezomib patients, total mean costs and median survival from start of relapsed/refractory treatment were c54,435 and 21.6 months. The proportion of patients still in follow-up at the end of data collection was slightly higher in bortezomib versus non-bortezomib patients (51% vs. 46%). Total mean costs for bortezomib patients did not differ signifi cantly when excluding patients still in follow-up. For non-bortezomib patients, total mean costs differed signifi cantly when excluding patients still in follow-up, mainly due to high costs of lenalidomide treatment, stem cell transplants and inpatient hospital stays. CONCLUSIONS: Our real-world data challenged the assessment of the incremental cost-effectiveness of bortezomib versus other treatments in the indication of relapsed/ refractory multiple myeloma. It was possible to estimate the cost and effects for bortezomib patients in daily practice to determine the real-world value. Data synthesis incorporating effectiveness for the relevant comparator might facilitate estimation of a valid ICER.
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PSY40 COST-EFFECTIVENESS OF PREGABALIN VERSUS USUAL CARE IN REFRACTORY OUT-PATIENTS WITH NEUROPATIC PAIN FOLLOWED IN PRIMARY CARE SETTINGS
de Salas-Cansado M 1 , Pérez C 2 , Saldaña MT 3 , Navarro A 4 , Rejas J 5 1 Trial Form Support Spain, Madrid, Spain; 2 Pain Clinic, Hospital de la Princesa, Madrid, Spain; 3 Primary Care Health Centre Raíces, Castrillón, Asturias, Spain; 4 Primary Care Health Centre Puerta del Ángel, Madrid, Spain; 5 Pfi zer España, Alcobendas/Madrid, Spain OBJECTIVES: Estimate the cost-effectiveness of Pregabalin (PGB) versus Usual Care (UC) in refractory out-patients with Neuropathic Pain (NeP) treated according to usual medical practice in Primary Care settings (PCS) in Spain. METHODS: Data extracted from a 12-week non-interventional prospective study conducted to ascertain the cost of NeP were used. PGB naïve patients treated with UC or PGB, matched by age (+5 years), sex and pain intensity (+5 pts), refractory (≥40VAS-McGill) to previous treatment during the prior 6 months, were selected in a 1:1 ratio. Patients could switch to PGB (monotherapy/add-on) or to UC (non-narcotics, opiates, antidepressants and/ or anticonvulsants). Time horizon was 12 weeks. Effectiveness was quality-adjusted life-years (QALY) gain. Perspectives of the National Health Service (NHS) and society (2006) were included, and expressed as an incremental cost-effectiveness ratio (ICER). Bootstrapping techniques (10,000 re-samples) were used to obtain the probabilistic ICER, its 95% percentile confi dence interval (CI) and the cost-effectiveness acceptability curve. RESULTS: A total of 160 patient-pairs were extracted. Compared with UC, PGB was associated with signifi cantly higher QALY gain; 0.0374 ± 0.0367 vs. 0.0224 ± 0.0313 (P < 0.001). Notably, although drug costs were higher for PGB (c251 ± 125 vs. c104 ± 121, P < 0.001), its QALY gain did not incur a higher overall total cost (c1335 ± 1302 vs. c1387 ± 1489; P = 0.587), nor higher health care costs (c529 ± 438 vs. c560 ± 672; p = 0.628). In fact, the ICER was dominant for total and health care costs, with CIs respectively, dominant-c17,268, and dominant-c6,508. ICER for drug costs was c10,672/QALY (dominant-c19,858). The 99% of the re-samples were below the threshold of c30,000/QALY. CONCLUSIONS: Versus usual care in the community medical setting, pregabalin is highly cost-effective in the treatment of refractory NeP patients. The high indirect costs and increased health care costs associated with the treatment of refractory patients, which offset higher cost of pregabalin, highlight the economic burden of the condition on society.
PSY41 COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN TWO LA COUNTRIES-COMPARISON WITH THE EUROPEAN EXPERIENCE
Alandete JC Janssen-Cilag, Bogota, Colombia OBJECTIVES: To evaluate cost-effectiveness of biologics used in patients with psoriasis in Colombia and Peru. METHODS: We estimated direct costs of etanercept, adalimumab, ustekinumab and infl iximab based on their labels for fi rst/induction year and second/maintenance year (EUR1 = COL$2340 = SOL$357). For etanercept we considered two induction schemes: 50 mg weekly 52 weeks-D1-and 100 mg 12 weeks followed by 50 mg 40 weeks-D2-. Effectiveness was evaluated as 75% reduction in Psoriasis Area and Severity Index-PASI 75-from meta-analysis presented by Hawkins et al. in the 14 th International ISPOR: infl iximab = 80%; ustekinumab = 69%; adalimumab = 59%; etanerceptD2-= 52%; etanerceptD1 = 39%. Infl iximab and ustekinumab effectiveness were not signifi cantly different. However, both were significantly superior to etanercept (D1 and D2). RESULTS: In Colombia, Ustekinumab was dominant (c29.012 in 2 years) generating cost savings of −c4.416 vs. etanerceptD1; −c7.411 vs. adalimumab; −c8.119 vs. etanerceptD2 and −c25,340 vs. infl iximab; with higher or same effectiveness than the other biologics used in that country. In Peru, all the options were more effective and more costly than the standard of care (etanerceptD1). The ICER per patient with PASI 75 of etanerceptD2, adalimumab, ustekinumab and infl iximab, compared to etanerceptD1 were c21.654; c19,860, c13,036 and c29,008, respectively. Then, the effi ciency frontier was formed by etanerceptD1, ustekinumab and infl iximab. Given evidence shows the last two products do not have effectiveness signifi cant differences, ustekinumab became the dominant option. An additional analysis was done supposing that infl iximab's effectiveness was superior to ustekinumab's. The ICER per patient with PASI 75 between these products was c220,352 in Colombia and c50,989 in Peru. These values were higher than Colombian and Peruvian health systems' willingness to pay per PASI 75 (c40.334 and c29,242, respectively), calculated based on average effectiveness and costs of biologics. CONCLUSIONS: In the studied LA countries, Ustekinumab resulted the most costeffective biologic, even being cost-saving in Colombia. These results corroborate those observed in European countries.
PSY42 COST-EFFECTIVENESS ANALYSIS OF BIOLOGICS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN THE PUBLIC HEALTH CARE SYSTEM OF BRAZIL
Morais AD, Ribeiro F Janssen-Cilag, São Paulo, SP, Brazil OBJECTIVES: To compare treatment costs and cost-effectiveness results for biologics approved for the treatment of moderate to severe psoriasis from the perspective of a public payer in Brazil. METHODS: Annual treatment costs were calculated based on the number of vials used, as defi ned in the label for each biologic, and from the price per vial. The prices of etanercept, adalimumab and infl iximab were obtained from purchase disclosures by the Brazilian Ministry of Health. As ustekinumab, the latest biologic approved for psoriasis, has not yet been purchased by that Ministry, its list price after deducting the mandatory discount for government sales (22.85%) was considered. The effectiveness of each treatment was defi ned by a recent metanalysis as the PASI75 response at the primary endpoint for each drug. The average patient weight was assumed at 70 kg. RESULTS: Ustekinumab has the lowest treatment cost across the biologics in both induction and maintenance years with the least number of vials used. With a total of 4 applications during a maintenance year, ustekinumab has the lowest treatment cost, followed by infl iximab (55% more expensive), adalimumab (62% more expensive) and etanercept (75% more expensive). Combining the cost and effectiveness results, ustekinumab has the lowest cost per response, followed by infl iximab (44% less cost-effective), adalimumab (104% lesss cost-effective) and etanercept (152% less cost-effective). CONCLUSIONS: With the lowest treatment cost, ustekinumab is an important treatment option in moderate to severe psoriasis. When comparing the cost-per-response across biologics, ustekinumab is further differentiated from the remaining biologics. Ustekinumab represents a rare situation in Brazil combining the lowest treatment cost and a high effectiveness result.
PSY43 ECONOMIC ANALYSIS OF RITUXIMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISOLONE IN THE TREATMENT OF PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN PORTUGAL
Pereira C 1 , Negreiro F 2 , Silva C 2 1 Roche Farmacêutica Quimica, Portugal, Amadora, Portugal, 2 Eurotrials-Consultores Científi cos, Lisbon, Portugal OBJECTIVES: Evaluate costs and benefi ts of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP) versus CVP alone in previously untreated patients with indolent non-Hodgkin lymphoma (NHL). METHODS: Cost-effectiveness (Life-years Gained-LYG) and cost-utility analysis (Quality Adjusted Life-years-QALYs) were performed for a time horizon of 10 years according to a Markov economic model with three health states ("progression free survival", "progression" and "death") and monthly cycles. Data from a phase III clinical trial (Marcus R. et al 2007) was used and expanded in the model to include unpublished 53-month median follow-up data. Survival after fi rst-line therapy was estimated from the Scotland and Newcastle Lymphoma Group registry data and utilities were derived from a UK study. Resource consumption was estimated by a Portuguese expert panel. Costs were calculated from the Portuguese Health System perspective through offi cial data with prices updated to 2010. Only direct medical costs were considered. Costs and consequences were discounted at 5% per annum. Deterministic and probabilistic sensitivity analyses were performed around assumptions on the time horizon, costs, utilities and excess mortality rate due to progression applied in the base-case analysis.
RESULTS:
The 10-year base-case analysis showed a lower total cost per patient with CVP alone (c88,373) versus R-CVP (c89,899). Life expectancy and quality-adjusted life expectancy per patient were higher with R-CVP (6.361 and 4.166, respectively) versus CVP alone (5.557 and 3.438, respectively), representing increases of 0.804 in LYG and 0.728 in QALYs gained. The incremental cost per QALY gained was c2097 (base-case) and c6006 considering a lifetime horizon (25 years). The sensitivity analyses confi rmed the robustness of the model. CONCLUSIONS: This study demonstrates that the combination R-CVP in previously untreated NHL patients improves life expectancy and is a cost-effective alternative to CVP in Portugal.
PSY44 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO GABAPENTIN AND PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN SPAIN
Nuijten M 1 , Hidalgo A 2 , Obradovic M 3 , Liedgens H 3 1 Ars Accessus Medica/Erasmus University Rotterdam, Jisp, The Netherlands; 2 Castilla-La Mancha University, Toledo, Spain; 3 Gruenenthal GmbH, Aachen, Germany OBJECTIVES: To assess the cost-effectiveness of using a lidocaine 5% medicated plaster in the treatment of post-herpetic neuralgia (PHN) compared with gabapentin and pregabalin from the perspective of the payer in Spain. METHODS: A Markov model was constructed to calculate the cost-effectiveness of gabapentin, pregabalin and lidocaine plaster in terms of the cost per quality-adjusted life-year (QALY) gained when used over a six-month time horizon in patients with PHN. The model structure allowed for differences in costs, utilities and transition probabilities between the initial 30-day run-in period and maintenance therapy. Transition probabilities were based on the comparative and long-term clinical trials identifi ed through a systematic literature review. Missing data, including resource utilization, were obtained from a Delphi panel, and cost data were obtained from the offi cial price/tariffs lists. Utilities were derived from the literature and were supplemented and validated by the Delphi panel.
RESULTS:
The total cost of treatment with the lidocaine plaster was c1414 per patient at a daily consumption of 1.1 plasters, compared with c1100 for gabapentin (average dosage 2100 mg/day during maintenance phase), and c1348 for pregabalin (average dosage 488 mg during maintenance phase). Lidocaine plaster generated 0.428 QALYs, compared with 0.339 for gabapentin, and 0.399 for pregabalin. Lidocaine plaster therefore had an incremental cost-effectiveness ratio of c3525/QALY gained relative to gabapentin at generic price, and c742/QALY relative to pregabalin. Scenario analyses and extensive one-way sensitivity analyses on all parameters including the time horizon confi rmed the robustness of the results. CONCLUSIONS: The lidocaine 5% plaster is a highly cost-effective treatment for PHN in Spain.
PSY45 PREGABALIN IS A COST-EFFECTIVE MEDICINE FOR REFRACTORY NEUROPATHIC PAIN IN SWEDEN
Sandelin R 1 , Prettyjohns M 2 , Lister SP 2 1 Pfi zer, Sollentuna, Sweden, Sweden; 2 Cardiff Research Consortium Ltd, Cardiff, UK OBJECTIVES: Patients refractory to older therapies for neuropathic pain (NeP) have few remaining therapeutic options. To demonstrate pregabalin's value to decision-makers, this study evaluates the cost-utility of pregabalin in the treatment of patients with refractory neuropathic pain in Sweden, from a health care and societal perspective. METHODS: A discrete event simulation (DES) model was constructed to compare pregabalin with usual care. Pain profi les were generated for the pregabalin and usual care cohorts using clinical data from a synthesis of fi ve non-randomised pregabalin studies in treatment-refractory patients. Utility data were generated from a UK survey of patients with NeP, which were used in a recent successful Health Technology Assessment (HTA) of pregabalin in the UK [1] . Cost data were generated from the Swedish TLV's product price database, a national NeP register, and a regional register study. Indirect costs were estimated from published sources. One-way, and probabilistic sensitivity analyses (PSA), evaluated uncertainty in the model's output. RESULTS: The incremental cost-effectiveness ratio (ICER) for pregabalin compared to usual care was 51,616 SEK/c5,364 (123,993 SEK/c12,886 excluding indirect costs). One-way sensitivity analyses confi rmed the clinical input data as the main driver of the model; even considerable changes to all other input parameters had only a modest effect on the ICER. The PSA generated an ICER of 41,634 SEK/c4,327 (with indirect costs included), suggesting that the model is relatively insensitive to the combined variation in all input parameters; this is evident in the ICER scatter, in which the costeffectiveness pairs are tightly grouped. CONCLUSIONS: Our study found pregabalin to be highly cost-effective compared to usual care in Swedish treatment-refractory patients. Moreover, the PSA showed pregabalin's favourable cost-effectiveness to be robust in all modelled scenarios, with an ICER well below a conservative threshold of 347,495 SEK / c36,113/£30,000. Patients with moderate to severe forms of psoriasis reveal lower quality of life. This QoL deterioration comes together with their productivity loss and disability. Therefore, we calculated indirect costs, from societal perspective, of psoriasis in Czech Republic. METHODS: This calculation was based on 6 months-retrospective self-reported questionnaire. We included 179 patients with psoriasis, aged 18-62 years either at working status, partly-disabled or fully-disabled. For calculation of indirect costs we included costs associated with absenteeism (number of missed workdays) and costs associated with disability pension. We used friction costs approach (FCA) with defi ned friction period of 6 months (130 workdays). The height of average monthly income in year 2009, c851.3 and height of average monthly partly-disability pension and fully-disability pension c229.44 and c365.61, respectively were used for calculation. Indirect costs were expressed as mean value per one patient with moderate to severe form of psoriasis per one year-2009. Clinical data (PASI score, BSA index and QoL) were collected by dermatologists. RESULTS: Average patients' age was 45.34 years (23-62 years), average time from diagnosis was 23.9 years. Mean BSA index and PASI score were 26.78% and 13.32, respectively. Occurrence of psoriatic arthritis was 34.1%. Percentage of fully-disabled and partly-disabled patients was 9.5 and 6.1%, respectively. 18.4% of patients reported incapacity to work with average duration of 28.8 workdays in previous 6 months. Mean costs associated with absenteeism, partly-disability pension and fully-disability pension were c214, c168 and c414, respectively. CONCLUSIONS: By using friction cost approach total mean indirect costs of patients with moderate to severe forms of psoriasis were c796 per patient per year. The height of indirect costs was correlated with PASI score, BSA index and QoL.
